Dicker Data (ASX: DDR) achieved another year of very strong profit growth, assisted by the acquisition of Exeed.

Camplify revenue growth of over 100% will catch investors eye, but the devil is in the detail…

Symbio is setting itself up for acquisitive growth in Asia, but the stock is arguably priced for perfection.

Sequoia Financial Group (ASX: SEQ) reported strong growth and has a very believable plan to keep it going for years to come.

The Ebos Group half year report showed decent growth, both organic and through acquisitions. But the Ebos share price is up, leading to a lower dividend yield.

My analysis of the Pro Medicus half year results suggest that the business is improving in quality as it grows.

Here is a list of ASX Small Cap Stocks results reporting dates, plus links to their results presentations, collated for your convenience.

The Audinate (ASX:AD8) H1 FY 2022 results were subdued at first glance, but key metrics imply the business continues to improve in quality.

Nanosonics shares dropped this morning when it updated the market on its half year revenue, and its distribution agreement with GE Healthcare.

Energy One’s acquisition of CQ Energy should create growth opportunities in renewable energy, but it also brings notable risks.

Quarterly reports of Rightcrowd, IntelliHR and Volpara update us on free cash flow and annualised recurring revenue growth…

By my reckoning this company is trading on about 15 times earnings and yielding at least 4% in dividends. And growth is likely, albeit not certain.

The Genetic Signatures (ASX:GSS) share price has dropped almost 10% despite reporting record receipts from customers.

The BeforePay share price is at 29% below the IPO price, but what does BeforePay the company actually do?

People generally prefer to believe what is comforting over the unpleasant truth, and investors can use that to profit.

I think the Australian Clinical Labs (ASX: ACL) is likely to fall in the short term as the Morrison government moves to restrict PCR testing.

The Ebos Group (ASX: EBO) retail equity offer has me considering if I want to increase my position, or arbitrage the discount for a profit.

The second half of 2021 saw my portfolio take a hit, as growth stocks entered a downturn…

This ASX listed med-tech company has an enterprise value of less than $200m, but has expanded its customer base significantly, as a result of the pandemic.

As we see out the end of 2021, all signs point to a bumpy start to 2022. Here’s how I’m thinking about inflation, Omicron, and the end of 2021.